12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane nab-paclitaxel: Additional Phase III data

Additional data from the open-label, international Phase III CA033 trial in 529 chemotherapy-naïve patients with stage IV metastatic melanoma showed that 150 mg/m 2 Abraxane given on days 1, 8 and 15 every 4 weeks led to PFS, the primary endpoint, of 4.8 months vs. 2.5 months for dacarbazine (p=0.044). Additionally, an interim analysis of OS showed that...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >